106 results
424B3
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement
4:53pm
CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS
PLAN OF DISTRIBUTION
LEGAL MATTERS
EXPERTS
WHERE YOU CAN FIND MORE INFORMATION
INCORPORATION OF CERTAIN … and the holder’s written consent.
Governing Law
The Placement Agent Warrants are governed by New York law.
CERTAIN U.S. FEDERAL INCOME TAX
424B5
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement for primary offering
4:52pm
. We will also include information in the prospectus supplement, where applicable, about material United States federal income tax considerations … for fixed rate debt securities.
United States federal income tax consequences and special considerations, if any, applicable to any such series
8-K
EX-4.3
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all … and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall
8-K
EX-4.1
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
share.
vi. Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other … sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any
8-K
EX-4.2
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
share.
vi. Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other … sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any
DEF 14C
qtdu0 5ttklc4
18 Mar 24
Information statement
4:59pm
PRE 14C
f63bzi b9chxniww
8 Mar 24
Preliminary information
4:31pm
424B3
iwyw v11212e
2 Feb 24
Prospectus supplement
12:00am
8-K
EX-4.1
j21 pxnsg30
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-4.2
vstfnepbw5ptt7
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-4.3
yeev8bmexlxf0bac p32
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.1
riey2ntn6ur5nw0hfh
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.4
uqgiefh
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.2
gdmvdr12h19 t9
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-10.2
m9mtwjrnb fu0bm4w2
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
424B4
ggfcfvu 5kj
2 Nov 23
Prospectus supplement with pricing info
9:00am